Results 131 to 140 of about 202,977 (306)

Evaluating Renal Disease in Pediatric‐Onset Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome

Arthritis &Rheumatology, EarlyView.
Objective We aimed to study the disease course, outcomes, and predictors of outcome in pediatric‐onset antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) affecting the kidneys. Methods Patients eligible for this study had a diagnosis of granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or ANCA‐positive pauci‐immune ...
Kirandeep K. Toor, Audrea Chen, David A. Cabral, Cherry Mammen, Else S. Bosman, Ye Shen, Jeffrey N. Bone, Damien Noone, Eslam Al‐Abadi, Susanne Benseler, Roberta Berard, Marek Bohm, Sirirat Charuvanij, Kathryn Cook, Paul Dancey, Samundeeswari Deepak, Ciaran Duffy, Barbara Eberhard, Melissa Elder, Dirk Foell, Dana Gerstbacher, Merav Heshin‐Bekenstein, Adam Huber, Karen E. James, Susan Kim, Marisa Klein‐Gitelman, Neil Martin, Flora McErlane, L. Nandini Moorthy, Charlotte Myrup, Phil Riley, Susan Shenoi, Vidya Sivaraman, Tamara Tanner, Stacey Tarvin, Linda Wagner‐Weiner, Rae S. M. Yeung, Kelly L. Brown, Kimberly A. Morishita, on behalf of the PedVas Investigators Network   +39 more
wiley   +1 more source

Rheumatology beyond 2000: wither or whither? [PDF]

, 1989
W. Watson Buchanan, Peter Brooks
openalex   +1 more source

Genetic data do not provide evidence that lower sclerostin is associated with increased risk of atherosclerosis: comment on the article by Zheng et al

Arthritis &Rheumatology, EarlyView.
James R. Staley, Olga Giannakopoulou, Gill Holdsworth, Martin Armstrong   +3 more
wiley   +1 more source

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial

Arthritis &Rheumatology, EarlyView.
Objective Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSCs) compared with monthly cyclophosphamide (CY).
George E. Georges, Dinesh Khanna, Mark H. Wener, Matthew G. Mei, Maureen D. Mayes, Robert W. Simms, Vaishali Sanchorawala, Chitra Hosing, Suzanne Kafaja, Attaphol Pawarode, Leona A. Holmberg, Jason Kolfenbach, Daniel E. Furst, Keith M. Sullivan, Suiyuan Huang, Ted Gooley, Richard A. Nash   +16 more
wiley   +1 more source

Physiotherapy in Rheumatology [PDF]

, 1982
Elizabeth Harvey
openalex   +1 more source

Reply

Arthritis &Rheumatology, EarlyView.
Jie Zheng, George Davey Smith, Jonathan H. Tobias   +2 more
wiley   +1 more source

Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low‐Back Pain With Modic Type 1 Changes: A Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Efficacy of a Tumor necrosis inhibitor in chronic low‐back pain with Modic type 1 changes: The BackToBasic study, A randomized controlled trial. Objective The efficacy of tumor necrosis factor inhibitors for treating chronic low‐back pain with Modic changes is uncertain.
Elisabeth Gjefsen, Lars C. Bråten, Erica Ponzi, Magnhild H. Dagestad, Gunn H. Marchand, Thomas Kadar, Gunnstein Bakland, Anne J. Haugen, Fredrik Granviken, Tonje W. Flørenes, Nils Vetti, Lars Grøvle, Aksel T. Nilsen, Astrid Lunestad, Thor E. Holmgard, Morten Valberg, Nils Bolstad, Ansgar Espeland, Jens I. Brox, Guro L. Goll, Kjersti Storheim, John‐Anker Zwart   +21 more
wiley   +1 more source

Outcome of Patients With Lupus Nephritis Treated With an Anti‐CD40 Monoclonal Antibody According to Kidney Biopsy Features

Arthritis &Rheumatology, EarlyView.
Objective A phase 2 trial tested different doses of the anti‐CD40 monoclonal antibody BI 655064 as an add‐on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo.
Martina Uzzo, Helmut Schumacher, Juergen Steffgen, Simone Deutschel, David Jayne, Ingeborg Bajema   +5 more
wiley   +1 more source

Editorial: Nuclear medicine in rheumatological diseases' therapy and diagnosis

Frontiers in Medicine, 2023
Giorgio Treglia, Giorgio Treglia, Giorgio Treglia, Clément Bailly, Clément Bailly   +4 more
doaj   +1 more source

Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq

Open Access Rheumatology: Research and Reviews, 2018
Nizar Abdulateef Al Ani,1 Faiq I Gorial,1 Saad Al-Sulaitti,2 Jasmine Abbas Humadi,3 Nabaa Ihsan Awadh,4 Mohamed Mounir,5 Yasser El Dershaby,5 Heather Jones,6 Nancy Sunna7 1Rheumatology Unit, Department of Medicine, College of Medicine, University of ...
Al Ani NA, Gorial FI, Al-Sulaitti S, Humadi JA, Awadh NI, Mounir M, El Dershaby Y, Jones H, Sunna N   +8 more
doaj